A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 23 May 2013 Planned End Date changed from 1 Nov 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov .
- 21 May 2012 Planned end date changed from 1 Feb 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov .